Analysis of programmed death-ligand 1 (PD-L1) expression, transforming growth factor (TGF)-β gene expression signatures (GES) and tumor-infiltrating immune cells (IC) in hepatocellular carcinoma (HCC): Rationale for targeting PD-L1-and TGF-β

被引：0
|
作者：
Zhang, Y. [1 ]
Naughton, B. J. [2 ]
Rolfe, P. A. [1 ]
Frick-Krieger, E. [3 ]
Dussault, I. [4 ]
Terracciano, L. [5 ]
Ihling, C. [6 ]
机构：
[1] EMD Serono Res & Dev Inst, R&D Global Early Dev, Billerica, MA USA
[2] EMD Serono Res & Dev Inst, Bioinformat, Billerica, MA USA
[3] Merck KGaA, RD EBP H, Darmstadt, Germany
[4] EMD Serono Res & Dev Inst, Clin Biomarkers & Compan Diagnost, Billerica, MA USA
[5] Univ Hosp Basel, Inst Pathol, Pathol, Basel, Switzerland
[6] Merck KGaA, CBD, Darmstadt, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1645P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Programmed Death-Ligand 1 (PD-L1) Expression in Pheochromocytoma: Clinicopathologic Correlation
    Xiong, Meng-Jun
    Kissick, Haydn
    Master, Viraj
    Osunkoya, Adeboye O.
    MODERN PATHOLOGY, 2019, 32
  • [22] Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer
    Govindarajan, Rangaswamy
    Gujja, Swetha
    Siegel, Eric R.
    Batra, Anu
    Saeed, Anwaar
    Lai, Keith
    James, Jennifer D.
    Fogel, Bradley J.
    Williamson, Stephen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (07): : 638 - 642
  • [23] Assessment of programmed death-ligand 1 (PD-L1) expression in different breast tumor subtypes
    Sobral-Leite, M.
    de Vijver, K. Van
    Kersten, K.
    Peters, D.
    Kok, M.
    Broeks, A.
    De Visser, K. E.
    Schmidt, M. K.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S128 - S128
  • [24] Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
    Nie, Hanxiao
    He, Tao
    Wang, Li
    Zhang, Ling
    ONCOTARGETS AND THERAPY, 2021, 14 : 1377 - 1385
  • [25] Programmed death-ligand 1 (PD-L1) expression in small cell carcinoma of bladder.
    Sanguino, Angela
    Samiei, Arash
    Pasricha, Gurleen
    Harinath, Lakshmi
    Miller, Ralph
    Lyne, John
    Silverman, Jan F.
    Mao, Shifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma
    Richter, Igor
    Jirasek, Tomas
    Cermakova, Eva
    Bartos, Jiri
    Buchler, Tomas
    Dvorak, Josef
    JOURNAL OF BUON, 2019, 24 (05): : 2155 - 2160
  • [27] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [28] The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma
    Gabrych, Anna
    Peksa, Rafal
    Kunc, Michal
    Krawczyk, Malgorzata
    Izycka-Swieszewska, Ewa
    Biernat, Wojciech
    Bien, Ewa
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [29] Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma
    Nam, Soo Jeong
    Kim, Young-Hoon
    Park, Ji Eun
    Ra, Young-shin
    Khang, Shin Kwang
    Cho, Young Hyun
    Kim, Jeong Hoon
    Sung, Chang Ohk
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 305 - 318
  • [30] Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma
    Soo Jeong Nam
    Young-Hoon Kim
    Ji Eun Park
    Young-shin Ra
    Shin Kwang Khang
    Young Hyun Cho
    Jeong Hoon Kim
    Chang Ohk Sung
    Cancer Immunology, Immunotherapy, 2019, 68 : 305 - 318
12345